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Abstract
Background: a-Santalol, an active component of sandalwood oil, has shown chemopreventive effects on skin
cancer in different murine models. However, effects of a-santalol on cell cycle have not been studied. Thus, the
objective of this study was to investigate effects of a-santalol on cell cycle progression in both p53 mutated
human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells to elucidate the
mechanism(s) of action.
Methods: MTT assay was used to determine cell viability in A431 cells and UACC-62; fluorescence-activated cell
sorting (FACS) analysis of propidium iodide staining was used for determining cell cycle distribution in A431 cells
and UACC-62 cells; immunoblotting was used for determining the expression of various proteins and protein
complexes involved in the cell cycle progression; siRNA were used to knockdown of p21 or p53 in A431 and
UACC-62 cells and immunofluorescence microscopy was used to investigate microtubules in UACC-62 cells.
Results: a-Santalol at 50-100 μM decreased cell viability from 24 h treatment and a-santalol at 50 μM-75 μM
induced G2/M phase cell cycle arrest from 6 h treatment in both A431 and UACC-62 cells. a-Santalol altered
expressions of cell cycle proteins such as cyclin A, cyclin B1, Cdc2, Cdc25c, p-Cdc25c and Cdk2. All of these
proteins are critical for G2/M transition. a-Santalol treatment up-regulated the expression of p21 and suppressed
expressions of mutated p53 in A431 cells; whereas, a-santalol treatment increased expressions of wild-type p53 in
UACC-62 cells. Knockdown of p21 in A431 cells, knockdown of p21 and p53 in UACC-62 cells did not affect cell
cycle arrest caused by a-santalol. Furthermore, a-santalol caused depolymerization of microtubules similar to
vinblastine in UACC-62 cells.
Conclusions: This study for the first time identifies effects of a-santalol in G2/M phase arrest and describes detailed
mechanisms of G2/M phase arrest by this agent, which might be contributing to its overall cancer preventive
efficacy in various mouse skin cancer models.
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Cancer is the second leading cause of death in the Uni-
ted States accounting for one of every four deaths
exceeded only by heart diseases. Among all types of can-
cers, skin cancer including basal cell carcinoma (BCC)
and squamous cell carcinoma (SCC) is the most com-
mon form of cancer in the United States with more
than one million cases diagnosed yearly leading to an
estimated 11,590 deaths in 2009 [1]. Therefore, the
development of effective chemopreventive or che-
motherapeutic agents is useful to address the risk of
cutaneous malignancies.
Recently, there has been a considerable interest in the
use of naturally occurring agents especially phytochem-
icals, minerals and vitamins for the chemopreventive
activity against various malignancies under both in vitro
and in vivo conditions [2,3]. More than 1000 phyto-
chemicals have shown cancer chemopreventive effects
and about 400 of them are currently under further
investigation [4-7]. One of such phytochemical is
a-santalol which has shown excellent chemopreventive
effects against skin cancer under both in vivo and
in vitro conditions [8-12].
a-Santalol is a major component of sandalwood oil
(Santalum album Linn, Indian sandalwood) which has
been traditionally used in the treatment of various skin
ailments. Our previous studies reported that topical
application of a-santalol (5%, w/v) showed significant
chemopreventive effects on 7, 12-dimethylbenz(a)
anthracene (DMBA)-initiated and 12-O- tetradecanoyl-
phorbol-13-acetate (TPA)-promoted skin cancer devel-
opment, and inhibited ornithine decarboxylase (ODC)
activity and DNA synthesis induced by TPA in both
CD-1 and SENCAR mice [8]; furthermore, a-santalol
(5%, w/v) application significantly inhibited skin tumor-
igenesis by UVB-initiated and TPA-promoted, DMBA-
initiated and UVB-promoted, and UVB-initiated and
UVB-promoted in SKH-1 hairless mice, and also sup-
pressed UVB-caused induction of epidermal ODC
activity in SKH-1 mice [9]. Dose-response experiment
indicated that 5% of a-santalol (w/v) application
resulted in a relatively higher inhibition of skin tumori-
genesis induced by UVB in SKH-1 mice [10]. Both in
vivo and in vitro models suggested that one of the pos-
sible mechanisms of its chemopreventive effects is
related to induction of apoptosis through both extrinsic
and intrinsic pathways [11,12]. In terms of mechanism
(s) of chemopreventive agents, in addition to the induc-
tion of apoptosis, studies in recent years are focused on
the modulation of cell survival pathways such as cell
cycle arrest, since disruption of the normal regulation
of cell cycle progression and division are important
events in the development of cancer [13]. However, to
our knowledge, the effects of a- s a n t a l o lo nc e l lc y c l e
have not been investigated. Thus, the objective of this
study was to determine the effects of a-santalol on dif-
ferent phases of cell cycle and proteins required for the
regulation of cell cycle progression and arrest in both
p53 mutated human epidermoid carcinoma A431 cells
and p53 wild-type human melanoma UACC-62 cells.
The results obtained from current study show that in
addition to induction of apoptosis by a-santalol as
reported previously [12], a-santalol caused G2/M phase
cell cycle arrest to decrease cell viability. In the mechan-
istic studies, alterations of cell cycle regulatory proteins
and complexes involved in the G2/M transition were
identified to further elucidate the mechanisms of che-
mopreventive effects against skin cancer by a-santalol.
Methods
Materials and reagents
Propidium iodide, RNase, N-2-hydroxyethylpiperazine-
N’-2- ethanesulfonic acid (HEPES), sodium chloride,
sodium dodecyl sulfate (SDS), triton, sucrose, phenyl-
methanesulphonylfluoride (PMSF), anti-a-tublin-FITC
antibody were purchased from Sigma Chemical Co. (St.
Louis, MO). Dulbecco’s modified eagle’sm e d i u m
(DMEM), RPMI-1640 fetal bovine serum (FBS), trypsin
EDTA, phosphate buffered saline (PBS) and DPBS were
from Mediatech, Inc. (Herndon, VA). Dimethyl sulfoxide
(DMSO) was obtained from Fisher Scientific (Fair Lawn,
NJ). Leupeptin and pepstatin were from Roche Diagnos-
tics GmbH (Mannheim, Germany). All primary antibo-
dies, secondary antibodies, RIPA lysis buffer, siRNA and
siRNA transfection reagent were from Santa Cruz Bio-
technology (Santa Cruz, CA). ECL Plus Kit was bought
from Amersham Biosciences (Piscataway, NJ). Other
reagents were obtained in their highest purity grade
available commercially.
Isolation of a-santalol
a-Santalol was isolated from sandalwood oil (Now
Foods, Glendale HTS., IL) by column chromatography
using n-Hexane: Ethyl acetate 3:1 as a solvent system.
The purity was assessed by gas chromatography [14].
Cell culture
Human epidermoid carcinoma A431 cell line and
human melanoma UACC-62 cell line were purchased
from American Type Culture Collection (ATCC, Mana-
ssas, VA). A431 Cells and UACC-62 cells were grown in
DMEM and in RPMI-1640 medium supplemented with
10% heated inactivated fetal bovine serum, 100 unit/mL
of penicillin and 100 μg/mL of streptomycin in a humi-
dified atmosphere containing 5% CO2 and 95% air at
37°C.
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a-Santalol was dissolved in DMSO to make 0.05 mol/L
stock solution, and stock solution of a-santalol was
diluted in growth medium at different concentrations
and immediately used. In all the assays, the final con-
centrations of DMSO in growth medium were 0.4%.
Determination of cell viability by MTT assay
Cell viability was determined by MTT assay as described
by Zhang et al. [15]. A431 cells were plated at a density
of 7,500 cells/well and UACC-62 cells in a 96-well plate.
After 24 hours, cells were treated as vehicle in growth
media as control or various concentrations of a-santalol
(10-100 μM) for 24, 48, and 72 h. At the end of each
treatment, MTT stock solution (5 mg/mL) was diluted
to 0.5 mg/mL by medium and immediately used. The
medium covering the cells was aspirated off, and then
cells were incubated with 50 μLo f0 . 5m g / m LM T T
solution for 4 hours at 37°C. Thereafter, 150 μLo f
DMSO was added to each well to dissolve dye crystal
formazan and the plate was allowed to stand for 1 hour
at 37°C, and then mixed with the microplate shaker for
5 minutes to make sure that all purple crystals were dis-
solved. Absorbance was measured by SpectraMax M2
microplate reader (Molecular Devices, Sunnyvale, CA) at
570 nm, with the absorbance at 650 nm to correct for
background in the presence of an appropriate blank
(without cells). The blank reading was subtracted from
experimental readings and cell viability was expressed as
the percentage of the absorbance values of a-santalol
treated groups to untreated controls.
Analysis of cellular DNA content by flow cytometry
A431 cells or UACC-62 cells were plated in 6-well
plates. After 24 hours, cells were treated as either
growth medium with 0.4% DMSO alone as control or
various concentrations of a-santalol (25 μM, 50 μM and
75 μM) for 6 h, 12 h, 24 h and 48 h respectively. At the
end of each treatment periods, cells were harvested by
trypsinization and washed twice with ice-cold PBS, and
then fixed with ice-cold 70% ethanol in DPBS at 4°C.
Fixed cells were then centrifuged and washed with stain-
ing buffer. After washing, the pellets were treated with
100 μL RNase A (1 mg/mL) for 30 min at 37°C. After
incubation, 900 μLo fs t a i n i n gb u f f e ra n d2 0μLo fp r o -
pidium iodide (1 mg/mL) were added to each sample
and incubated in the dark for 30 min. The samples were
then analyzed with BD FACScan™ flow cytometry (BD
Biosciences, San Jose, CA) using CellQuest Software
(BD Biosciences, San Jose, CA).
Immunoblotting
A431 cells (3.5 × 10
6)o rU A C C - 6 2c e l l s( 1×1 0
6)w e r e
plated to each 100 mm culture dish before drug
treatment. After 24 hours of cell attachment, cells were
treated as either growth medium with 0.4% DMSO
alone as control or concentrations of a-santalol (25 μM,
50 μMa n d7 5μM) for 12 h, 24 h and 48 h respectively.
At the end of the treatment, cells were lysed and protein
concentrations were determined by BCA™ protein assay
kit (Pierce, Rockford, IL) with albumin as a standard as
described by Zhang et al. [15]. All samples (30-80 μgo f
proteins) were subjected to 7.5%-15% sodium dodecyl
sulfate polyacrylamide gel (SDS-PAGE). The proteins in
gels were transferred to nitrocellulose membranes. After
blocking the membranes with 5% non-fat milk, mem-
branes were probed with the appropriate dilution of pri-
mary antibodies followed by appropriate horseradish
peroxidase (HRP) conjugated secondary antibody and
ECL Plus detection kit (Amersham Biosciences, Piscat-
away, NJ) by using a UVP Biochem Gel Documentation
system (UVP, Inc., Upland, CA).
Transfection of small interfering RNA (siRNA)
p21, p53 siRNA and siRNA transfection reagent were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA)
following Vendor’s protocol. Briefly, A431 cells and
UACC-62 cell were seeded into 6-well plates for about
24 h, when they had reached about 60% confluence. Then,
the cells were incubated with siRNA transfection reagent
and siRNA for 10 h. Next, 2 times of normal growth med-
ium was added to the tranfection mixture. After additional
18 h, medium was replaced by normal growth medium for
another 18-24 h. Then, the cells were harvested and
seeded into 6-well plates and 100 mm dishes. After cell
attachment (18-24 h), various concentrations of a-santalol
were treated. At end of each treatment (12 h or 24 h), cells
were fixed for the analysis of DNA content by flow cyt-
ometer and proteins were extracted for the immunoblot-
ting to confirm the efficacy of each transfection. When the
transfection efficacy was more than 50%, the data for the
analysis of DNA content were used.
Immunofluorescence microscopy of UACC-62 cells
UACC-62 cells were cultured in chamber slides and
treated with different concentrations of a-santalol
(50 μM-100 μM), taxol (1 nM-20 nM) and vinblastine
(1 nM-20 nM) as two positive controls. After 24 h treat-
ment, cells were fixed with 4% paraformaldehyde. Cells
were then blocked with 5% bovine serum albumin and
incubated with anti-a-tubulin-FITC and 4′-6-diamidino-
2-phenylindole (DAPI) for 2 h at 37°C. Coverslips were
mounted and examined with an Olympus AX70 fluores-
cence microscope.
Statistical Analysis
Data were analyzed with INSTAT software (Graph Pad,
S a nD i e g o ,C A ) .A N O V Af o l l o w e db yT u k e yp o s tt e s t
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ferent a-santalol treatment groups with untreated con-
trols. Significance in all the experiment was considered
at P < 0.05. Values were expressed as mean ± the stan-
dard deviation of the mean.
Results
a-Santalol treatment inhibited cell viability in A431 cells
and UACC-62 cells
Our first aim was to investigate whether a-santalol
treatment imparts anti-proliferative effect against
human epidermoid carcinoma A431 cells and human
melanoma UACC-62 cells, as this is the first study to
assess the effect of a-santalol on a solid tumor
(UACC-62) cell line. As shown in Figure 1A, for 12 h
treatment, a-santalol treatment starting at 75 μM
significantly inhibited cell viability of A431 cells as
compared to control. For 24 h treatment, a-santalol at
50 μM-100 μM resulted in 26.7%-56.8% and 20.2%-
51.1% decrease of cell viability in A431 and UACC-62
respectively as shown in Figure 1B. For 48 h treatment,
a-santalol at 50 μM-100 μM inhibited 59.1%-91.6%
and 38.9%-71.9% of cell viability as compared to their
individual control in A431, and UACC-62 respectively
as shown in Figure 1C.
Overall, a-santalol treatment inhibited the cell viabi-
lity of two cell lines in a concentration- and time-
dependent manner. Therefore, further experiments were
performed to investigate whether the decrease of cell
viability in skin cancer cell lines by a-santalol treatment
is related to the alteration in normal cell cycle
distribution.
Figure 1 Effects of a-santalol on cell viability in A431 and UACC-62. Cells were treated with a-santalol (0-100 μM) for 12 h (A),2 4h(B)
and 48 h (C). At the end of the respective treatments, MTT assay was performed as detailed in the materials and methods. Values are mean ±
SD of three independent observations. *, P < 0.05 indicates significantly lower after a-sanatalol treatment as compared to their individual control
cells.
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In order to better understand the mechanism of inhibi-
tion of cell viability, we investigated the effects of
a-santalol on various phases of cell cycle in both A431
cells and UACC-62 cells. Analysis of cell cycle phases
was performed by flow cytometry after the treatment of
cells with a-santalol. To our knowledge, this is the first
study to assess the effects of a-santalol on cell cycle
progression in any cell line.
A ss h o w ni nF i g u r e2 ,f o rA 4 3 1c e l l s ,a-santalol at 25
μM produced relatively small changes in DNA distribu-
tion between all phases of cell cycle. Whereas, starting
at 6 h treatment, a-santalol at 50 μMa n d7 5μM
resulted in a significantly (P < 0.05) higher number of
A431 cells in the G2/M phase as measured by the distri-
bution of DNA content compared to the control. Similar
findings were observed at 12 h (Figure 2C and 2D) and
75 μM for 24 hr treatment (Figure 2E and 2F). The
increase in cell population in G2/M phase caused by a-
santalol was associated with a corresponding shift in the
population of cells mainly in G0/G1 phase.
However, a-santalol at 50 μM for 24 h treatment in
A431 cells did not significantly increase the number of
cells in the G2/M phase. As shown in Figure 2E, 50 μM
of a-santalol for 24 h treatment resulted in a strongly
different histogram as compared with other concentra-
tions and other time periods, since a large number of
cells (25.2% ± 3.7%) were observed before G0/G1 phase
marked as Sub-G1, which were apoptotic cells [16].
a-Santalol induced G2/M phase cell cycle arrest in UACC-
62 cells
A431 cells are p53 mutated skin cancer cell line [17]. As
p53 plays an important role in regulation of cell cycle
progress, the effects of a-santalol on cell cycle progres-
sion in a p53 wild-type UACC-62 cell line [18], were
also investigated. As shown in Figure 3, for UACC-62
cells, starting at 6 h treatment, a-santalol at 50 μMa n d
75 μM significantly caused a G2/M phase arrest in
UACC-62 cells. Similar findings were observed at 12 h
(Fig 3C and 3D) and 24 hr treatment (Fig 3E and 3F).
The increasing cell population in G2/M phase caused by
a-santalol is largely due to the decreasing cell popula-
tion in G0/G1 phase. Table 1 summarized the percen-
tage of G2/M phase induction caused by a-santalol as
compared to control in both cell lines. a-Santalol has
similar effects on cell cycle progression in UACC-62
cells as well as A431 cells for most concentrations and
time periods. These results suggest that a-santalol
causes G2/M phases arrest in both wild-type and mutant
p53 skin cancer cell lines.
a-Santalol changed expressions of proteins involved in
the G2/M phase transition in A431 cells
Cell cycle progression and arrest processes are depen-
dent on the levels of cyclins, cylin-dependent kinases
(CDKs) and their inhibitors, thus we have also investi-
gated the changes in the expression of cell cycle protein
levels in A431 cells after a-santalol treatment. Marked
changes in the expression of proteins that are known to
play a role in G2/M phase progression were observed in
the presence of a-santalol in A431 cells.
As shown in Figure 4A, cyclin A, a protein involved in
both S and G2 phase was significantly down-regulated
at 48 h time point with 75 μM doses. The expression of
Cdk2 which associates with cyclin A for cell cycle pro-
gression was found to be decreased at 48 h with 75 μM
of a-santalol treatment. Next, cyclin B1, a protein
involved in M phase was investigated. Normally, cyclin
B degradation occurs at the end of mitotic phase. How-
ever, in the presence of a-santalol, the level of cyclin B1
protein was increased as early as 12 h and 24 h treat-
ment at 50-75 μM and remained undegradable till 48 h
with 25-50 μMo fa-santalol. Cyclin B1 activates Cdc2.
Therefore, we determined the impact of a-santalol on
the expressions of Cdc2. As presented in the Figure 4A,
a-santalol only inhibited the expression of Cdc2 for 48
h treatment and a-santalol did not affect the expression
of Cdc2 at other concentrations and other time period
treatments.
Cdks are maintained in an inactive state through the
phosphorylation of Thr 14 and Tyr 15. The rate limiting
step in the activation of Cdks is dephosphorylation of
these residues by Cdc25 phosphatases [19]. There are
three mammalian cdc25 homologues: Cdc25A, Cdc25B
and Cdc25C [19]. In order to better understand the
effects of a-santalol on Cdks, we further determined the
impact of a-santalol on the expressions of Cdc25A,
Cdc25B and Cdc25C in A431 cells. Of all the Cdc25
phosphatases tested, significant changes in the expres-
sion pattern were observed only in Cdc25C with
a-Santalol. As presented in the Figure 4A, a-santalol
caused a concentration- and time-dependent inhibition
of Cdc25C expression. Cdc2 can be activated through
the dephosphorylation of Thr 14 and Tyr 15 by phos-
pharylating Cdc25C to p-cdc25C at Ser 216 [19]. Even
though the expressions of Cdc25C were inhibited by a-
santalol treatment, the expressions of p-Cdc25C were
increased by a-santalol treatment as one more band of
p-Cdc25C was induced as early as 12 h treatment of a-
santalol indicating that the up-regulation of p-Cdcd25C
by a-santalol treatment might cause A431 cells to
decrease the synthesis of Cdc25C
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involved in the G1 phase in A431 cells
Since a-santalol caused cell accumulation in the G2/M
phase and altered the expression of proteins involving in
the G2/M phase, we also wanted to know whether
a-santalol had effects on proteins involving in the G1
phase in A431 cells. As shown Figure 4B, various con-
centrations of a-santalol for different time period treat-
ments did not alter the expressions of cyclin D1, Cdk4
and Cdk6. These results indicate that a-santalol
Figure 2 Effects of a-santalol on the distribution of A431 cells in the different phases of the cell cycle. A431 Cells were treated with a-
santalol (0 μM-75 μM) for 6 h (A and B), 12 h (C and D) and 24 h (E and F). At the end of respective treatment, cells were harvested and
digested with RNase. Cellular DNA was stained with propidium iodide and analyzed by flow cytometer as described in the Materials and
Methods. Panels A, C and E are histograms representing different time treatment with a-santalol. Data in Panel B, D and F from the cell cycle
distribution were summarized and presented as the mean ± SD of three observations. *, P < 0.05 indicates statistical significance in a-sanatlol
treated groups as compared to the control in A431 cells.
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in A431 cells.
a-Santalol inhibited expressions of proteins involved in
the G2/M phase transition in UACC-62 cells
Since a-santalol caused G2/M phase arrest in both A431
cells and UACC-62 cells, we wanted to know whether
molecular events that are responsible for G2/M phase
arrest caused by a-santalol treatment would be same in
both cell lines. Thus, expressions of G2/M phase regula-
tory proteins such as cyclin A, Cdk2, cyclin B, Cdc2,
Cdc25c and p-Cdc25C were assessed in UACC-62 cells
as well. As shown in Figure 5A, a-santalol at 50 μM
and 75 μM almost completely blocked the expressions
Figure 3 Effects of a-santalol on the distribution of UACC-62 cells in the different phases of the cell cycle. UACC-62 Cells were treated
with a-santalol (0 μM-75 μM) for 6 h (A and B), 12 h (C and D) and 24 h (E and F). Data were summarized and presented as the mean ± SD of
three observations. *, P < 0.05 indicates statistical significance in a-sanatlol treated groups as compared to the control in UACC-62 cells.
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cells. The expressions of cyclin B were unchanged at
12 h and 24 h treatment, but significantly inhibited at
48 h treatment in UACC-62. p-Cdc25C remained
unchanged with a-santalol treatment. The effects of a-
santalol on other proteins such as Cdk2, Cdc2, Cdc25C
were similar in A431 cells and UACC-62 cells.
a-Santalol induced expression of p21 and inhibited
expression of mutant p53 in A431 cells
In addition to cyclins and CDKs, p21 is a cyclin-
dependent kinase (cdk) inhibitor, which tightly regu-
lates the activities of cyclin/CDK enzyme complex. As
shown in Figure 6A, in A431 cells, the expression
of p21 was strongly increased starting at 25 μMo f
a-santalol for 24 h treatment. p21 can be activated
through either p53-dependent pathway or p53-indepe-
dent pathway. Since A431 cells are p53 mutated cell
line (19), the up-regulation of p21 by a-santalol in
A431 cells is not mediated through a p53-dependent
p a t h w a y .M o r e o v e r ,i tw a sf o u n dt h a te x p r e s s i o n so f
mutated p53 were decreased after treatment of differ-
ent concentrations of a-santalol as shown in Figure
6A. Inhibition of mutated p53 may also contribute to
the chemopreventive effects of a-santalol in vivo ani-
mal models [8-11].
Table 1 Comparison of G2/M phase induction by a-santalol in A431 cells and UACC-62 cells
Time of
treatment
Conc. of a-santalol
(μM)
Percentage of G2/M phase induction by a-santalol as compared to control *
p53 mutated human epidermoid carcinoma A431
cells
p53 wild-type human melanoma UACC-62
cells
6 h 50 49.1 70.9
75 48.8 65.2
12 h 50 171.1 148.7
75 235.5 149
24 h 50 27.2 226
75 285 305.5
*: Data were expressed as the percentage of the induction of a-santalol treated groups in G2/M phase to untreated controls.
Figure 4 Effects of a-santalol on cell cycle regulators in A431 cells as determined on the follows, (A) proteins involved in G2/M phase
and (B) proteins involved in G1 phase. Cells were treated with different concentrations of a-sanatlol for different time periods, and then cells
were collected by brief trypsinization. Total cell lysates were prepared and loaded to SDS-PAGE and Western blotting. Membranes were then
probed with different primary antibodies followed by appropriate secondary antibody and ECL detection. Photographs of the chemiluminescent
detection of the blots, which were representative of three independent experiments, are shown. b-actin was used to verify equal loading of the
samples. Data were represented as at least three independent observations. IB, immunoblotting.
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on p21 in A431 cell
In order to elucidate the role of upregulation of p21 on
its overall cell cycle progression by a-santalol, p21
siRNA was used to inhibit p21 expression in A431 cells
as confirmed by Western blotting. As shown in Figure
6B, the percentage of cells in G2/M phase caused by a-
santalol treatment was similar in both normal A431cells
and p21 down-regulated A431 cells, which suggested
that G2/M phase arrest caused by a-santalol is not
dependent on p21 in A431 cells.
a-Santalol induced expression of p21 and p53 in UACC-
62 cells
In UACC-62 cells, the expressions of both p21 and
wild-type p53 were increased by a-santalol treatment
starting from 12 h treatment as shown in Figure 7A.
However, as can be seen from Figure 7B and 7C, either
down-regulation of p21 or p53 in UACC-62 cells by
siRNA did not significantly changed percentage of cells
in G2/M phase caused by a-santalol as compared to
normal UACC-62 cells. These results revealed that G2/
M phase arrest caused by a-santalol in UACC-62 cells
is not dependent on both p21 and p53.
a-Santalol caused disruption of the cellular microtubule
network in UACC-62 cells
Most antimicrotubule agents that target the cellular
microtubule network result in an aberrant formation of
the mitotic spindle, subsequent blockage of the cell
cycle in G2/M phase and causing apoptotic cell death
[20,21]. Since a-santalol caused G2/M phase arrest and
Figure 5 Effects of a-santalol on cell cycle regulators in UACC-62 cells as determined on proteins involved in G2/M phase.D a t aw e r e
represented as at least three independent observations.
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Page 9 of 15Figure 6 Effects of a-santalol on p21 and p53 in A431 cells. (A). Protein levels of p21 and p53 after a-santalol treatment in A431 cells were
evaluated by Western blotting. (B). Cell cycle distribution in p21 siRNA transfected A431 cells was analyzed by flow cytometer. Data were
summarized and presented as the mean ± SD of three observations. For each p21 siRNA transfection in A431 cells, Western blotting was
performed to ensure the inhibition of p21 protein expression.
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Page 10 of 15apoptosis, we examined whether it affects the organiza-
tion of microtubules in UACC-62 cells, which are rela-
tively big cells and their microtubules are easily
visualized compared to A431 cells. UACC-62 cells were
treated with different concentrations of a-santalol (50
μM-100 μM), taxol (1 nM-20 nM), vinblastine (1 nM-20
nM) as presented in Figure 8. After 24 h treatment,
microtubules in the control cells were clearly seen to
traverse intricately throughout the cell and individual
microtubules often appeared long and relatively straight.
In contrast, a-santalol caused a dose-dependent loss of
microtubule network, since the antibody-based fluores-
cence of microtubules was dispersed throughout the
cytoplasm. These effects are similar to that exerted by
vinblastine, a known inhibitor of tubulin polymerization,
but different from that of taxol which stabilized micro-
tubules causing them to form long polymerized micro-
tubule bundles. Thus, we concluded that a-santalol
likely caused microtubule depolymerization in UACC-62
cells.
Figure 7 Effects of a-santalol on p21 and p53 in UACC-62 cells. (A). Protein levels of p21 and p53 after a-santalol treatment in UACC-62
cells were evaluated by Western blotting. Cell cycle distribution in (B) p21 siRNA and (C) p53 siRNA transfected UACC-62 cells was analyzed by
flow cytometer. Data were summarized and presented as the mean ± SD of three observations. For each p21 siRNA or p53 siRNA transfection in
UACC-62 cells, Western blotting was performed to ensure the inhibition of p21 or p53 protein expressions.
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In our previous studies, a-santalol, a naturally occurring
terpenoid, has shown to have chemopreventive effects
on both DMBA-initiated and TPA-induced skin cancer
development in CD-1 and SENCAR mice [8] and UVB-
induced skin tumor developments in SKH-1 hairless
mice [9-11]. In vitro studies also demonstrated that a-
santalol could be effective against skin carcinogenesis in
mouse models through induction of apoptosis via cas-
pase activation together with dissipation of mitochon-
dria membrane potential and cytochrome c release in
A431 cells [12].
The development of cancer is also associated with dis-
orders in the regulation of the cell cycle in addition to
Figure 8 Effects of a-santalol (50 μM-100 μM), taxol (1 nM-20 nM) and vinblastine (1 nM-20 nM) on microtubules in UACC-62 cells.
Cells were exposed to drug for 24 h before fixation and staining with an anti-tubulin antibody as described in Materials and Methods.
Microtubule morphology (green) and nuclei conterstained with DAPI (blue) were examined by immunofluorescence microscopy.
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lian cells coordinate cell growth, genome replication and
cell division. Two irreversible events subdivided the cell
cycle into distinct phases: DNA replication of cells is
defined as S phase and cell division is called as M
phase. G1 and G2 are two gap phases where cells grow
and carry out additional functions [23].
Even though our previous studies showed that a-santalol
could induce apoptosis through caspase-dependent path-
way in both in vivo [11] and in vitro in A431 cells [12], the
effects of a-santalol on the cell cycle have not been studied
yet. Accordingly, in this study, the effects of a-santalol on
cell cycle and proteins involved in the cell cycle regulation
in two human skin cancer-derived cancer cell lines, epider-
moid carcinoma A431 cells and melanoma UACC-62 cells
were investigated. The hypothesis in this study was
whether a-santalol could affect the cell cycle progression
which may contribute to its chemopreventive effects in
animal models.
Our data demonstrated that treatment of a-santalol
resulted in a concentration- and time- dependent inhibi-
tion of cell viability on A431 cells and UACC-62 cells as
determined by MTT assay. Treatment of a-santalol (50
μM) for 12 h did not significantly decrease cell viability
of A431 and UACC-62 cells. However, flow cytometric
analysis of cell cycle distribution revealed that a-santalol
(50-75 μM) from 6 h treatment to 24 h treatment led to
a 49%-285% and 71%-306% induction of G2/M phase in
A431 cells and UACC-62 cells respectively as compared
to control cells. These findings indicated that G2/M
phase cell cycle arrest induced by a-santalol treatment
may be one of the mechanisms which results in a
decrease of cell viability in A431 and UACC-62 cells
after a-santalol treatment.
Cell cycle progression is tightly regulated by cyclin/
cyclin-dependent kinase (Cdks) complexes [24-27]. For
instance, cyclin D/Cdk4 and Cdk6 drive the sequential
progression from G1 to S phase; cyclin A/Cdk2 and
Cdc2 (Cdk1) complexes control the S and G2 phases;
and cyclin B/Cdc2 complex drives the G2/M transition
as well as processes during mitosis [23]. Accordingly, in
the present paper, the effects of a-santalol on proteins
involved in the G2/ Mp h a s ew e r ef i r s ti n v e s t i g a t e d .
Results revealed that a-santalol treatment has different
impacts on cell cycle regulatory proteins in A431 cells
and UACC-62 cells, even through a-santalol caused G2/
M phase arrest in both cell lines.
In A431 cells, expressions of cyclin A, Cdk2 and Cdc2
were decreased only after treated by a high concentra-
tion of a-santalol (75 μM) for 48 h. However, expres-
sions of cyclin B1 were increased as early as 12 h
treatment. In UACC-62 cells, expressions of cyclin A
were fully inhibited starting from 24 h treatment and
both cyclin A/Cdk2 and cyclin B1/Cdc2 complexes were
decreased by a-santalol treatment. It is known that the
activation of cyclin B1/Cdc2 complex is required to
entry into mitosis through dephosphorylation of inhibi-
tory sites of Cdc2 by phosphorylating Cdc25C to p-
Cdc25C [28]. As we compared immunoblotting data of
p-Cdc25C in A431 cells and UACC-62 cells, it was
found that one more band of p-Cdc25C was induced by
a-santalol treatment in A431 cells only which may con-
tribute to the activation of cyclin B/Cdc2 complex in
A431 cells. Moreover, cyclin B degradation is essential
for completion of mitosis; whereas overexpression of
stable cyclin B1 entailed metaphase arrest [29]. Thus,
increasing cyclin B1 by a-santalol treatment in A431
cells might induce cell cycle arrest in the mid-metaphase
of mitosis [30]; whereas, decreasing cyclin A and cyclin
B1 by a-santalol in UACC-62 cells might induce cell
cycle arrest in G2 phase before entry into mitosis [31].
Since A431 cells express the mutated form of the P53
gene with substitution at codon 273 (His273) [17] and
UACC-62 cells are wild-type p53 cells [18], we wanted
to know whether p53 plays any role on the observed dif-
ferences between two cell lines. P53, a tumor suppressor
acts as a checkpoint regulator of cell cycles, contributing
to cell cycle arrest in the G1 [32,33], G2 [34,35] phases
by a multiple pathways. In the classical p53-dependent
pathway G2/M phase arrest, activation of p53 interacts
with response elements present on the promoter region
of p21 to increase expression of p21, which subse-
quently interacts with CDKs and cyclins to affect cell
cycle arrest [23]. Here in the present studies, the expres-
sions of p21 were increased by a-santalol treatment
in both cell lines; the expressions of mutated p53, that
is overexpressed in most of cancer cells [36], were
decreased after a-santalol treatment in A431 cells
and expressions of wild-type p53 were increased by a-
santalol in UACC-62 cells, all of which may contribute
to a-santalol’s overall chemopreventive effects against
skin cancer. However, knockdown of either p21 or wild-
type p53 did not change G2/M phase arrest caused by
a-santalol, which suggested that a-santalol induced
G2/M phase arrest independently of p21 and p53.
Conclusion
The present study demonstrated that in addition to
induction of apoptosis by a-santalol observed in in vitro
and in vivo studies [11,12], a-santalol also inhibits
human epidermoid carcinoma A431 cell growth and
human melanoma UACC-62 cells in vitro through
G2/M phase arrest independently on p21 and p53. a-
Santalol may cause metaphase of mitosis arrest in A431
cells through up-regulation of cyclin B; whereas, in
UACC-62 cells, a-santalol induced cell arrest in G2
phase by down-regulation of both cyclin A and cyclin B
complexes resulting in microtubule depolymerization.
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effects of a-santalol on melanoma cells, which may pro-
vide data for the future study of a-santalol on mela-
noma cancer in animal models. Based on this study,
a-santalol could be a potential agent against skin cancer
development. Future studies on the effects of a-santalol
on detailed mechanisms of cell cycle arrest and other
signal pathways for in vitro cell lines and in vivo animal
models are needed to further elucidate the detailed
mechanism(s) of action of a-santalol on skin cancer
chemoprevention.
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